Abnormal expression of Tim-3 antigen on peripheral blood T cells is associated with progressive disease in osteosarcoma patients

FEBS Open Bio

Volumn 6, Issue 8, 2016, Pages 807-815

  Liu, Hongliang ^a   Zhi, Liqiang ^a   Duan, Ning ^a   Su, Pengxiao ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Diagnosis; Osteosarcoma; T lymphocytes; Tim 3 protein

Indexed keywords

GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 2; TUMOR NECROSIS FACTOR;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER PATIENT; CANCER STAGING; CASE CONTROL STUDY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SERUM; TUMOR GROWTH; YOUNG ADULT;

EID: 85070485871     PISSN: None     EISSN: 22115463     Source Type: Journal    
DOI: 10.1002/2211-5463.12079     Document Type: Article

References (28)

1. Luetke A, Meyers PA, Lewis I and Juergens H (2014) Osteosarcoma treatment where do we stand? A state of the art review Cancer Treat Rev 40, 523-532
2. Mialou V, Philip T, Perol D, Berard P, Raimondo G, Pacquement H, Zucker JM and Kalifa C (2001) Metastatic osteosarcoma: prognosis factors and treatment. Bull Cancer 88, 1129-1135.
3. Zhu C, Anderson AC and Kuchroo VK (2011) TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 350, 1-15.
4. Huang Y, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen B, Melum E, Pertel T et al. (2014) CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 517, 386-390.
5. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK (2005) The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6, 1245-1252.
6. Webster RM (2014) The immune checkpoint inhibitors: where are we now? Nat Rev Drug Discov 13, 883-884
7. Anderson AC (2014) Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2, 393-398.
8. Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L and Ma C (2012) Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol 137, 978-985
9. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, Sun J, Yang Q, Zhang X and Lu B (2012) TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS One 7, e30676.
10. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Kuchroo V and Zarour HM (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8 + T cell dysfunction in melanoma patients. J Exp Med 207, 2175-2186.
11. Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S et al. (2014) PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res 74, 1045-1055.
12. Huang X, Bai X, Cao Y, Wu J, Huang M, Tang D, Tao S, Zhu T, Liu Y, Yang Y et al. (2010) Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 207, 505-520.
13. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK and Anderson AC (2010) Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J Exp Med 207, 2187-2194.
14. Anderson AC (2012) Tim-3, a negative regulator of anti-tumor immunity. Curr Opin Immunol 24, 213-216
15. Shang Y, Li Z, Li H, Xia H and Lin Z (2013) TIM-3 expression in human osteosarcoma: correlation with the expression of epithelial-mesenchymal transition-specific biomarkers. Oncol Lett 6, 490-494.
16. Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E, Papp Z and Falus A (2007) TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol 127, 906-914.
17. Jiang J, Jin MS, Kong F, Cao D, Ma HX, Jia Z, Wang YP, Suo J and Cao X (2013) Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One 8, e81799
18. Han S, Feng S, Xu L, Shi W, Wang X, Wang H, Yu C, Dong T, Xu M and Liang G (2014) Tim-3 on peripheral CD4(+) and CD8(+) T cells is involved in the development of glioma. DNA Cell Biol 33, 245-250
19. Xiao T, Zhang L, Chen L, Liu G, Feng Z and Gao L (2014) Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma. Tumour Biol 35, 7951-7956.
20. Ferris RL, Lu B and Kane LP (2014) Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 193, 1525-1530.
21. Wang L, Zhao C, Peng Q, Shi J and Gu G (2014) Expression levels of CD28, CTLA-4, PD-1 and Tim-3 as novel indicators of T-cell immune function in patients with chronic hepatitis B virus infection. Biomed Rep 2, 270-274.
22. Guo L, Yang X, Xia Q, Zhen J, Zhuang X and Peng T (2014) Expression of human T cell immunoglobulin domain and mucin-3 (TIM-3) on kidney tissue from systemic lupus erythematosus (SLE) patients. Clin Exp Med 14, 383-388.
23. de Kivit S, Lempsink LJ, Plants J, Martinson J, Keshavarzian A and Landay AL (2014) Modulation of TIM-3 expression on NK and T cell subsets in HIV immunological non-responders. Clin Immunol 156, 28-35.
24. Han Q, Shi H and Liu F (2016) CD163(+) M2-type tumor-associated macrophage support the suppression of tumor-infiltrating T cells in osteosarcoma. Int Immunopharmacol 34, 101-106.
25. Irie A, Yamauchi A, Kontani K, Kihara M, Liu D, Shirato Y, Seki M, Nishi N, Nakamura T, Yokomise H et al. (2005) Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res 11, 2962-2968.
26. Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G et al. (2012) Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56, 1342-1351.
27. Wiersma VR, de Bruyn M, van Ginkel RJ, Sigar E, Hirashima M, Niki T, Nishi N, Samplonius DF, Helfrich W and Bremer E (2012) The glycan-binding protein galectin-9 has direct apoptotic activity toward melanoma cells. J Invest Dermatol 132, 2302-2305.
28. Dango S, Sienel W, Schreiber M, Stremmel C, Kirschbaum A, Pantel K and Passlick B (2008) Elevated expression of carcinoembryonic antigenrelated cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in nonsmall-cell lung cancer. Lung Cancer 60, 426-433.